|
Miltenyi Biotec
cd19car fmc63 apc fmc63 derived human cd19 car 130 127 344 rea1297 miltenyi biotec Cd19car Fmc63 Apc Fmc63 Derived Human Cd19 Car 130 127 344 Rea1297 Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63+cd19/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pm42876290-371-203-212 Average 93 stars, based on 1 article reviews
cd19car fmc63 apc fmc63 derived human cd19 car 130 127 344 rea1297 miltenyi biotec - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
cd19 car fmc63 idiotype antibody, reafinity Cd19 Car Fmc63 Idiotype Antibody, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63+cd19/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/custom%40130-127-342%4042526444 Average 93 stars, based on 1 article reviews
cd19 car fmc63 idiotype antibody, reafinity - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
cd19 car fmc63 idiotype ![]() Cd19 Car Fmc63 Idiotype, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63+cd19/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pmc13376164-408-15-20 Average 93 stars, based on 1 article reviews
cd19 car fmc63 idiotype - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
anti car ![]() Anti Car, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63+cd19/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pm42020353-187-19-20 Average 93 stars, based on 1 article reviews
anti car - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
cd19 ![]() Cd19, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63+cd19/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pmc13106092-71-17-21 Average 93 stars, based on 1 article reviews
cd19 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
rea1297 miltenyi ![]() Rea1297 Miltenyi, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63+cd19/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pm41962541-134-13-14 Average 93 stars, based on 1 article reviews
rea1297 miltenyi - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Azenta
cd19 targeting fmc63 single chain variable fragment scfv ![]() Cd19 Targeting Fmc63 Single Chain Variable Fragment Scfv, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63+cd19/cd19+chain+fmc63+fragment+scfv+single+targeting+variable/pmc13034291-310-1-9 Average 86 stars, based on 1 article reviews
cd19 targeting fmc63 single chain variable fragment scfv - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
anti cd19 car fmc63 idiotype antibody ![]() Anti Cd19 Car Fmc63 Idiotype Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63+cd19/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pm41062320-33-28-38 Average 93 stars, based on 1 article reviews
anti cd19 car fmc63 idiotype antibody - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
Journal: Nature Communications
Article Title: Simultaneous orthogonal cell engineering by a single CRISPR-Cas9 polyfunctional editor
doi: 10.1038/s41467-026-72846-2
Figure Lengend Snippet: A Polyfunctional editing strategy for the epi-silencing of B2M and TET2 and insertion of the CD19–28ζ CAR:ΔLNGFR construct into TRAC . B Left: percentages of the indicated T cell populations at day 14 after poly-editing (mean ± SD of 7 blood donors). TCR + : TCR-positive cells (green bar). TCR - : TCR-negative cells (light blue bar). TCR - /ΔLNGFR + : cells negative for endogenous TCRs and positive for ΔLNGFR (lilac bar). B2M - : B2M-negative cells (gray bar). B2M + : B2M-positive cells (white bar). Right: representative flow cytometry dot plots of poly-edited T cells showing expression of the TCRs and ΔLNGFR (left plot) and, within the TCR - /ΔLNGFR + cells, of B2M (right plot). C Fold-change in TET2 (light blue bars) and B2M (gray bars) expression in poly-edited vs . mock-treated cells (mean ± SD of 7 blood donors). D Schematic of the in vivo experiment. NSG mice were injected with GLuc.NALM-6 cells and, 7 days later, with the indicated T cell populations. Peripheral blood was collected at the indicated time points to measure tumor growth, phenotype human T cells, and quantify cytokine release. Mock: mock-transfected T cells. CAR-T Δ LNGFR : T cells expressing CD19–28ζ CAR:ΔLNGFR from TRAC . Poly-edited cells: T cells expressing CD19–28ζ CAR:ΔLNGFR from TRAC with epi-silencing of B2M and TET2 . E Tumor growth (left; mean ± SEM) and survival (right) curves over 20 days post-transplantation of the indicated T cell populations. n = 6 mice for Mock; n = 12 mice for each other group. ** p = 0.0075, *** p = 0.0008 by Mantel-Cox (log-rank) test. F Circos plots from CAST-Seq analyses of triple KO (left) and poly-edited (right) T cells ( n = 2 experimental replicates). Triple-KO cells were transfected with mRNA encoding Cas9 and the TRAC gRNA, together with gRNA B#6 and gRNA TE#19 . For poly-editing, the TRAC gRNA and the selected guide combinations for B2M and TET2 were used. Aberrations at the TRAC locus are in violet; translocations between TRAC and either B2M or TET2 are in blue; translocations between TRAC and OT sites of all gRNAs are in gray. G Number of unique CAST-Seq reads corresponding to either aberrations (violet bars) or translocations (gray bars) at the TRAC locus in the indicated treatments. Graphs were generated using GraphPad Prism (GraphPad Software). Source data are provided as a file.
Article Snippet: LNGFR; 130-113-422, Miltenyi), CD3 (345763, BD Biosciences), HLA-ABC (565332, BD Biosciences), HLA-E (130-117-402, Miltenyi), and
Techniques: Construct, Flow Cytometry, Expressing, In Vivo, Injection, Transfection, Transplantation Assay, Generated, Software
Journal: Nature Communications
Article Title: Simultaneous orthogonal cell engineering by a single CRISPR-Cas9 polyfunctional editor
doi: 10.1038/s41467-026-72846-2
Figure Lengend Snippet: A Scatter plot comparing whole-transcriptome analyses of T cells treated with the tripartite ETR and either full-length or truncated gRNAs targeting CD3D (left) or TGFBR2 (right) ( n = 2 experimental replicates). Data are expressed as log 2 TPM of mapped reads. B Polyfunctional editing strategy used to epi-silence CD3D and TGFBR2 and insert the scHLA-E:CD19–28ζ CAR cassette into exon 1 of B2M . C Left: percentages of the indicated T cell populations as measured by flow cytometry 14 days after polyfunctional editing (mean ± SD of 7 blood donors). HLA-ABC + : HLA-ABC-positive cells (light yellow bars); HLA-ABC - : HLA-ABC-negative cells (blue bars); CD19-CAR - : cells negative for the expression of the CD19–28ζ CAR (gray bars); CD19-CAR + : cells positive for the expression of the CD19–28ζ CAR (lilac bars); CD3 + : CD3-positive cells; CD3 - : CD3-negative cells; HLA-E - : HLA-E-negative cells; HLA-E + : HLA-E-positive cells. Right: representative flow cytometry dot plots of poly-edited T cells showing the expression levels of the HLA-ABC and CD3 (left plot) and, within the double-negative cells, of HLA-E and CD19-CAR (right plot). D Fold-change in the expression levels of CD3D (green bars) and TGFBR2 (orange bars) in poly-edited cells relative to mock-treated cells, 14 days post-editing (mean ± SD of 7 blood donors). Graphs were generated using GraphPad Prism (GraphPad Software). Source data are provided as a file.
Article Snippet: LNGFR; 130-113-422, Miltenyi), CD3 (345763, BD Biosciences), HLA-ABC (565332, BD Biosciences), HLA-E (130-117-402, Miltenyi), and
Techniques: Flow Cytometry, Expressing, Generated, Software
Journal: Frontiers in Oncology
Article Title: Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells
doi: 10.3389/fonc.2026.1774431
Figure Lengend Snippet: Determination of the limit of detection (LOD) and lower limit of quantification (LLOQ) for the two-step method. CAR-T cell absolute counts were measured in 31 negative control samples from patients not treated with CD19 CAR-T cells. The mean background signal is represented by the blue line. LOD was defined as mean + 3 standard deviations (SD), and LLOQ as mean + 10 SD.
Article Snippet: New CAR detection reagent (CDR) directly coupled to fluorochrome, either BCMA (BCMA CDR-PE, Miltenyi Biotec 130-133-888) or
Techniques: Negative Control
Journal: Frontiers in Oncology
Article Title: Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells
doi: 10.3389/fonc.2026.1774431
Figure Lengend Snippet: Gating strategy for the single-step method. Absolute counting beads were excluded based on scatter and fluorescence properties. Dead cells were excluded using 7-aminoactinomycin D (7-AAD). CD45-positive leukocytes were selected, and lymphocytes were identified according to side scatter (SSC) characteristics. CD3-positive T cells were gated, and CAR-T cells were defined as viable CD45+/CD3+/CAR+ events using directly fluorochrome-conjugated CAR detection reagents (CD19 or BCMA). CD4 and CD8 subpopulations were subsequently identified within the CAR-positive T-cell compartment. Absolute quantification was calculated using TruCount beads according to the manufacturer’s formula.
Article Snippet: New CAR detection reagent (CDR) directly coupled to fluorochrome, either BCMA (BCMA CDR-PE, Miltenyi Biotec 130-133-888) or
Techniques: Fluorescence, Quantitative Proteomics
Journal: Frontiers in Oncology
Article Title: Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells
doi: 10.3389/fonc.2026.1774431
Figure Lengend Snippet: Determination of LOD and LLOQ for the single-step method. CAR-T cell absolute counts were measured in 10 negative control samples from patients not treated with CD19 or BCMA CAR-T cells. The blue line represents the mean background signal. LOD was defined as mean + 3 SD and LLOQ (green dashed line) as mean + 10 SD.
Article Snippet: New CAR detection reagent (CDR) directly coupled to fluorochrome, either BCMA (BCMA CDR-PE, Miltenyi Biotec 130-133-888) or
Techniques: Negative Control